ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Hyperphosphataemia,Phosphorus metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
2,1,Hyperphosphataemia,Phosphorus metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
3,1,Urinary retention,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
4,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
4,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
5,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
6,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
6,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
6,3,Cholangiocarcinoma,Bile duct neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
6,4,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
6,5,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
6,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
6,7,Metastatic neoplasm,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
6,8,Neck pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
6,9,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
7,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
7,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
7,3,Alopecia,Alopecias,Skin appendage conditions,Skin,N
7,4,Blood phosphorus increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
7,5,Carbohydrate antigen 19-9 increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
7,6,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
7,7,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
7,8,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
7,9,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
7,10,Dry throat,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
7,11,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
7,12,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
7,13,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
7,14,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
7,15,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
7,16,Nail discolouration,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
7,17,Nail infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
7,18,Nasal congestion,Nasal congestion and inflammations,Upper respiratory tract disorders (excl infections),Resp,N
7,19,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
7,20,Onychoclasis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
7,21,Onycholysis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
7,22,Plantar fasciitis,Musculoskeletal and connective tissue infections and inflammations NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
7,23,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
7,24,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
7,25,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
8,1,Hypercalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
8,2,Osteoporosis,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
9,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
9,2,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
9,3,Cholangiocarcinoma,Bile duct neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,Y
9,4,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
9,5,Hyperphosphataemia,Phosphorus metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
9,6,Intestinal obstruction,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
9,7,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
9,8,Skin induration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
10,1,Acute biphenotypic leukaemia,Leukaemias acute NEC,Leukaemias,Neopl,N
10,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
10,3,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
10,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
11,1,Blood parathyroid hormone decreased,Parathyroid analyses,Endocrine investigations (incl sex hormones),Inv,N
11,2,Drug effective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
11,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
12,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
12,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
12,3,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
12,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
12,5,Hyperphosphataemia,Phosphorus metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
12,6,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
12,7,Nail infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
12,8,Nail toxicity,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
12,9,Onycholysis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
12,10,Paronychia,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
12,11,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
12,12,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
12,13,Therapy partial responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
13,1,Bacterial nail infection,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
13,2,Cholangiocarcinoma,Bile duct neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
13,3,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
14,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
14,2,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
14,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
14,4,Hypophosphataemia,Phosphorus metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
15,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
15,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
16,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
16,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
17,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
17,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
18,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
18,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
18,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
19,1,Optic neuropathy,Visual pathway disorders,Vision disorders,Eye,N
20,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
20,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
21,1,Cholangiocarcinoma,Bile duct neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
21,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
21,3,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
21,4,Serous retinal detachment,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
22,1,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
23,1,Cholangiocarcinoma,Bile duct neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
23,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
23,3,Nail bed disorder,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
24,1,Cholangiocarcinoma,Bile duct neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
24,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
25,1,Adenocarcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
25,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
25,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
26,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
26,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
26,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
26,4,Parathyroid tumour malignant,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
26,5,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
26,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
27,1,Adenocarcinoma of salivary gland,Salivary gland neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
27,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
27,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
28,1,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
28,2,Nail toxicity,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
28,3,Nail toxicity,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
28,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
28,5,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
29,1,Blood magnesium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
29,2,Blood phosphorus increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
29,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
29,4,Drug effective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
29,5,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
29,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
29,7,Osteosclerosis,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
30,1,Cutaneous calcification,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
30,2,Hypercalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
30,3,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
30,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
